Effect of Omega-3 supplementation in patients with multiple sclerosis
Phase 3
Recruiting
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20240702062304N1
- Lead Sponsor
- Abadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients with MS (diagnosis of MS based on McDonald's criteria)
Age 18 to 85 years
All types of MS (relapsing-remitting and progressive types)
Treated with MS course-modifying drugs at a fixed dose for 6 months before study enrollment
Exclusion Criteria
Participants in other trials except the present clinical trial
Recurrence or treatment with corticosteroids in the last month
Simultaneous treatment with antibiotics and antihypertensive drugs
Other acute or severe diseases except MS
Pregnancy
Current or past history of ventricular arrhythmia
A general health condition that interferes with participation in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum interferon-gamma level. Timepoint: Interferon gamma serum levels will be measured before and after the period of use (3 months) in the drug and placebo groups. Method of measurement: Using a specialized kit for measuring interferon gamma by ELISA method.
- Secondary Outcome Measures
Name Time Method Serum interferon- gamma level. Timepoint: Before the start of the intervention - day 1 of the study and after the end of the intervention - day 90 of the study. Method of measurement: Using a specialized kit for measuring interferon gamma factor in human serum by ELISA method.